Clinical trial for Alzheimer Disease
Official title Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
ClinicalTrials.gov ID: NCT06385106
What this study is testing
- What it's testing
- Previous studies have shown that repetitive transcranial magnetic stimulation (rTMS) can improve cognitive function in Alzheimer's disease (AD), but studies on the improvement of sleep disorders in AD are limited.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 to 80
You may be able to join if
- Participant meets 2014 IWG-2 criteria for hippocampal amnestic syndrome, typical of AD, with progressive episodic memory impairment confirmed by...
- Age range: 55-80 years.
- No visual or hearing impairment.
- Right-handed.
- Han nationality.
You likely can't join if
- History of seizures or epilepsy diagnosis;
- Stroke history;
- Nervous system diseases causing brain dysfunction (schizophrenia, severe anxiety/depression, dementia, Huntington's, brain tumors, Parkinson's...
- Severe liver/kidney/lung dysfunction, anemia, gastrointestinal disease, arrhythmia, recent MI;
- Barbiturate/benzodiazepine use within 2 weeks;
- MRI/TMS contraindications (metallic implants);
See the full eligibility criteria
- Participant meets 2014 IWG-2 criteria for hippocampal amnestic syndrome, typical of AD, with progressive episodic memory impairment confirmed by neuropsychology.
- Age range: 55-80 years.
- No visual or hearing impairment.
- Right-handed.
- Han nationality.
- Signed informed consent.
- Reliable caregivers as information providers.
- MMSE score: 10-27; CDR: 0.5-2 points.
- If receiving approved AD treatment (e.g., acetylcholinesterase inhibitor or memantine), dose must be stable for ≥3 months prior to screening and unchanged unless medically necessary.
- History of seizures or epilepsy diagnosis;
- Stroke history;
- Nervous system diseases causing brain dysfunction (schizophrenia, severe anxiety/depression, dementia, Huntington's, brain tumors, Parkinson's, metabolic encephalopathy, encephalitis, MS, epilepsy, brain trauma...
- Severe liver/kidney/lung dysfunction, anemia, gastrointestinal disease, arrhythmia, recent MI;
- Barbiturate/benzodiazepine use within 2 weeks;
- MRI/TMS contraindications (metallic implants);
- Systemic diseases causing cognitive impairment (hypothyroidism, folate/B12 deficiency, infections, alcohol/drug abuse);
- Aphasia, consciousness disturbance, inability to cooperate;
- TMS/tDCS/DBS has been processed;
- Underlying pathology other than AD;
- Focal brain lesions on T1/T2 images;
- Refusal to sign informed consent.
The study team makes the final eligibility decision.
Where it is enrolling
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Hangzhou, Zhejiang, China. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.